证券代码：688062 证券简称：迈威生物 公告编号：2025-056 1 | 修订前内容 | 修订后内容 | | --- | --- | | 商品）。（除依法须经批准的项目外， | （除依法须经批准的项目外，凭营业执 | | 凭营业执照依法自主开展经营活动）许 | 照依法自主开展经营活动）许可项目： | | 可项目：药品生产；药品委托生产；药 | 药品生产；药品委托生产；药用辅料生 | | 用辅料生产；保健食品生产；食品生产； | 产；保健食品生产；食品生产；药品批 | | 药品批发；药品零售；药用辅料销售； | 发；药品零售；药用辅料销售；特殊医 | | 特殊医学用途配方食品生产；食品销 | 学用途配方食品生产；食品销售；食品 | | 售；食品互联网销售；药品进出口。（依 | 互联网销售；药品进出口。（依法须经 | | 法须经批准的项目，经相关部门批准后 | 批准的项目，经相关部门批准后方可开 | | 方可开展经营活动，具体经营项目以相 | 展经营活动，具体经营项目以相关部门 | | 关部门批准文件或许可证件为准） | 批准文件或许可证件为准） | 除上述条款修订之外，《公司章程》中其他内容不变，相关变更 ...

《公司章程修正案》（2025 年 10 月修订） 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程 指引》，结合公司实际业务开展情况，公司计划将原有经营范围中的人体基因诊 断与治疗技术开发、细胞技术研发和应用等经营范围删除，并拟对《公司章程》 相关条款进行修订，具体情况如下： 迈威（上海）生物科技股份有限公司 | 修订前内容 | 修订后内容 | | --- | --- | | 第二章 | 公司的经营宗旨和经营范围 | | 第十四条 经依法登记，公司的经营范 | 第十四条 经依法登记，公司的经营范 | | 围是：一般项目：技术服务、技术开发、 | 围是：一般项目：技术服务、技术开发、 | | 技术咨询、技术交流、技术转让、技术 | 技术咨询、技术交流、技术转让、技术 | | 推广；医学研究和试验发展；人体基因 | 推广；医学研究和试验发展；人体基因 | | 诊断与治疗技术开发；细胞技术研发和 | 诊断与治疗技术开发；细胞技术研发和 | | 应用；租赁服务（不含许可类租赁服 | 应用；租赁服务（不含许可类租赁服务）； | | 务）；第一类医疗设备租赁；第二类医 | 第一类医疗设备租赁；第二类医疗 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-057 迈威（上海）生物科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 召开日期时间：2025 年 10 月 24 日 15 点 00 分 召开地点：上海市浦东新区李冰路 576 号创想园 3 号楼 103 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 24 日 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 ...

迈威（上海）生物科技股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 10 月 | | | 迈威（上海）生物科技股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，保证股东在迈威（上海）生物科技股份有 限公司（以下简称"公司"）依法行使股东权利，确保 2025 年第二次临时股东 大会会议的正常秩序和议事效率，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》 以及《迈威（上海）生物科技股份有限公司公司章程》（以下简称"《公司章 程》"）《迈威（上海）生物科技股份有限公司股东大会议事规则》等有关规 定，特制定本须知，请全体出席股东大会的人员自觉遵守。 一、 为确认出席大会的股东或代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者予以配合。 二、 经公司审核后符合参加本次股东大会条件的股东（含股东代理人）、 董事、监事、高级管理人员及其他出席人员方可出席本次会议；公司有权拒绝 不符合条件的人士进 ...

Core Insights - In September, a total of 335 companies on the Sci-Tech Innovation Board were investigated by institutions, with 17 companies receiving over 100 inquiries each [1] - The most investigated companies included Juhe Materials, Maiwei Bio, Juguang Technology, Lankai Technology, and Jingzhida, with inquiry counts of 370, 340, 305, 231, and 194 respectively [1] - Key sectors attracting attention were semiconductors, automation equipment, photovoltaic equipment, specialized equipment, and bioproducts [1] Company Developments - Juhe Materials announced plans to acquire SK Enpulse's blank mask business for 68 billion KRW, aiming to enhance its strategic layout and address domestic semiconductor material shortages [2][3] - Maiwei Bio formed a partnership with Aditum Bio to establish Kalexo Bio and secured a global exclusive licensing agreement for a cardiovascular siRNA drug [2] - Zhongkong Technology introduced the concept of "industrial embodied intelligence," aiming to integrate autonomous intelligence into the entire production process [3] Sector Focus - Institutions showed significant interest in companies within the chip interconnection, optical interconnection, battery, and energy storage sectors [4] - Lankai Technology is advancing its MXC chip and PCIe Retimer chip, which are crucial for AI server applications, enhancing bandwidth and reducing latency [5][6] - Xiatuo New Energy is focusing on solid-state battery materials and has achieved stable production of oxide solid-state electrolytes [7][8] Financial Performance - Hai Moxing reported a 350 million CNY inventory impairment in the first half of the year but expects improvement in the coming quarters [9] - Mei Ai Technology anticipates a long-term increase in overall gross margin, driven by a higher proportion of consumable products and expanding overseas market share [10] - Jingchen Co. noted a significant increase in inventory due to a surge in orders, with a record shipment volume in the second quarter [10]

Core Insights - In the third quarter, nearly 3,000 A-share listed companies were investigated by institutions such as securities companies, fund companies, and insurance firms [1] - The leading company in institutional research was Huichuan Technology, which received over 400 institutional inquiries [2][13] - The "hard technology" sectors, including integrated circuits, electronic components, and application software, attracted significant institutional attention [3][17] Securities Companies - CITIC Securities conducted the highest number of investigations, totaling 1,002, with the top three companies of interest being Chaohongji, Wentai Technology, and Liugong [5][7] - The top ten securities companies by investigation frequency were listed, with CITIC Securities leading [6][7] Insurance Companies - Major insurance companies such as Ping An Pension, Changjiang Pension, and Taiping Pension each conducted over 100 investigations [8] - The top ten insurance companies by investigation frequency were detailed, with Ping An Pension leading [9] Foreign Institutions - Foreign institutions, including Point72 Asset Management and Goldman Sachs, ranked high in the number of investigations conducted [10] - The top ten foreign institutions by investigation frequency were provided, highlighting their focus on specific companies [11] Company Research Focus - Huichuan Technology plans to invest 8% to 10% of its revenue in R&D, focusing on software and overseas market products [14] - Maiwei Bio-U is exploring liver-targeting and CNS-targeting for its siRNA projects [14] Industry Trends - The AI sector is expected to remain a focal point in the A-share market, with predictions of steady growth in the computer industry [17][18] - Recommendations include focusing on AI applications, computing power, and related sectors such as industrial software and internet financial software [18]

Core Viewpoint - The pharmaceutical sector in the Asia-Pacific market experienced a significant decline, with various indices showing notable drops, particularly in the weight loss drugs, innovative drugs, and CRO sectors [1][2]. Group 1: Market Performance - The A-share pharmaceutical and biotechnology sector saw a downturn, with weight loss drug index dropping by 1.56%, innovative drug index by 0.61%, and CRO index by 0.40% [2]. - Individual stocks such as Sunflower (向日葵) fell over 10%, while Aosaikang (奥赛康) and Guangshengtang (广生堂) also experienced significant declines of 9.02% and 6.56% respectively [3]. Group 2: Hong Kong and Japan Market Impact - The Hang Seng Biotechnology Index opened down nearly 2% and continued to decline, with companies like MicroPort Medical (微创医疗) and BeiGene (百济神州) showing notable drops of 5.47% and 4.75% respectively [4]. - In Japan, companies such as Sumitomo Pharma (住友制药) and Daiichi Sankyo (第一三共) also faced declines exceeding 4% and 3% respectively [4]. Group 3: External Factors - The recent announcement by U.S. President Trump regarding a new round of high tariffs on imported goods, including a punitive 100% tariff on patented and branded pharmaceuticals, is expected to impact the pharmaceutical industry significantly [5].

Group 1 - The A-share market saw a widespread decline in pharmaceutical stocks, with notable drops including Sunflower, Hanyu Pharmaceutical, and Kailaiying, each falling over 3% [1] - The U.S. President announced a new round of high tariffs on various imported products, including a 100% tariff on all brands and patented pharmaceutical products starting October 1 [1] Group 2 - Specific stock performance data shows that ST Complex dropped by 4.98%, with a total market value of 3.886 billion, and a year-to-date decline of 12.94% [2] - Sunflower's market value is 11.1 billion, with a year-to-date increase of 166.98%, despite a recent drop of 3.89% [2] - Hanyu Pharmaceutical's market value stands at 19.8 billion, with a year-to-date increase of 73.62%, and a recent decline of 3.20% [2] - Kailaiying's market value is 39.1 billion, with a year-to-date increase of 44.26%, and a recent drop of 3.01% [2] - Other companies such as Maiwei Bio, Zhaoyan New Drug, and Kanglong Chemical also experienced declines of over 2% [1][2]

9月25日，迈威生物涨1.33%，成交额6.55亿元。两融数据显示，当日迈威生物获融资买入额1.02亿元， 融资偿还7559.66万元，融资净买入2659.40万元。截至9月25日，迈威生物融资融券余额合计7.33亿元。 融资方面，迈威生物当日融资买入1.02亿元。当前融资余额7.32亿元，占流通市值的7.00%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，迈威生物9月25日融券偿还200.00股，融券卖出2200.00股，按当日收盘价计算，卖出金额 11.26万元；融券余量1.56万股，融券余额79.71万元，超过近一年80%分位水平，处于高位。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 截至6月30日，迈威生物股东户数1.79万，较上期增加11.66%；人均流通股11379股，较上期减少 10.44%。2025年 ...

Investment Rating - The industry rating is "Overweight" (maintained) [5] Core Insights - The collaboration between Maiwei Biotech, Yingsi Intelligent, and Haoyuan Pharmaceutical aims to create a novel ADC (Antibody-Drug Conjugate) compound library covering hundreds of targets, accelerating the industrialization of next-generation ADC drugs, which are considered a promising direction in cancer treatment [5][6] - This partnership highlights a shift in China's pharmaceutical innovation model from a singular "independent R&D" approach to a more collaborative ecosystem that integrates strategic alliances and shared research platforms, which helps mitigate early-stage R&D risks and optimizes resource allocation [7] Summary by Sections Recent Industry Performance - Over the past 12 months, the industry has shown a relative return of 5.97% compared to the CSI 300 index, with an absolute return of 42.2% [3] Investment Highlights - The collaboration combines strengths from various fields: Maiwei Biotech's experience in antibody drug development, Yingsi Intelligent's AI technology for target discovery and molecular design, and Haoyuan Pharmaceutical's expertise in high-end chemical raw materials [7] - The ADC drugs are positioned in a rapidly growing global market, with the collaboration aiming to systematically lay out core resources for future ADC drug development [7] - The report suggests monitoring the capital market movements of the collaborating companies, as their progress may act as a catalyst for stock price changes [7] Recommendations - The report recommends focusing on the entire ADC industry chain, including upstream CXO companies with advanced toxin-Linker technology, midstream innovative pharmaceutical companies with leading ADC platforms, and downstream large pharmaceutical companies with strong commercialization capabilities in oncology [7] - Specific companies to watch include Maiwei Biotech, Haoyuan Pharmaceutical, Rongchang Biotech, WuXi AppTec, Kailaiying, Nanfeng Technology, and Dongfulong [7]